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Abstract 
The purpose of this study was to evaluate whether topical application of superoxide dismutase with 
cell penetrating peptide (HIV-TAT) could protect against skin damage induced by UVB irradiation in 
human. The permeability through stratum corneum of large proteins linked to TAT peptide was firstly 
confirmed by confocal microscopy and tape stripping. Ten healthy volunteers with either Fitzpatrick 
skin type II or III were recruited in this clinical study. TAT-SOD (300 units/cm
2
) and vehicle cream 
were applied on two symmetric areas of both inner upper arms 1 hour prior to UVB irradiation. After 
one hour of pretreatment, subjects received 10 incremental doses of UVB on pretreated areas. 24 
hours later, erythema, blood flow and apoptotic cells were measured. Pretreatment with TAT-SOD 1 
hour prior to UVB radiation promoted a mean minimal erythema dose (MED) increase of 36.6 ± 18.4% 
(P = 0.013<0.05. n=10) compared to vehicle control. The median blood flow values of all subjects 
following 2 and 3-MED of UVB were 107.8 ± 51.0 units and 239.5 ± 88.0 units respectively, which 
accounts for 26 % and 25 % decrease with respect to vehicle groups. These data suggest that 
TAT-SOD significantly suppresses UVB induced erythema formation and blood flow rise. 
Furthermore, the pretreatment with TAT-SOD 1 hour prior to 2-MED of UVB irradiation reduced the 
apoptotic sunburn cell formation by 47.6 ± 8.6 % (p<0.0001) in all subjects. Evaluating results 
generated from all measurements, we conclude that topical application of TAT-SOD significantly 
attenuates UVB-induced skin damage in man. These biological effects of TAT-SOD are probably 
  
mediated via its free radical scavenging properties, clearly differentiating it from other physical 




Ultraviolet irradiation in sunlight generates reactive oxygen species (ROS) in skin that can oxidize 
nucleic acids, proteins and lipids, resulting in acute and chronic skin damage. The acute effects 
include erythema, tanning, and immune suppression. Long-term adverse effects of UV exposure are 
photoaging and photocarcinogenesis [1,2]. UVB (280-320nm) makes up around 5% of terrestrial 
ultraviolet radiation and is generally regarded as the prime cause for direct DNA damage in skin, but 
also generates reactive oxygen species (ROS), while the substantial amount of ROS generated by 
UVA (320-400nm) are more responsible for photoaging and photocarcinogenesis [3-5].  
 
To protect against ROS damage, the skin is well equipped with a large network of enzymatic 
antioxidants, such as superoxide dismutase (SOD) and catalase, and non-enzymatic antioxidants, 
which function in synergy to neutralize oxidative stress [6]. Numerous studies have shown that the 
SOD activity is drastically depleted after UV irradiation, leading to oxidative stress and the 
progression of chronic skin damage [7-10]. Nevertheless, the reduction can be compensated by 
exogenous supplementation or endogenous up-regulation of SOD, as a result of which keratinocytes 
are more resistant to oxidative stress induced injury. 
Indeed, previous studies have elicited many valuable clues indicating that the up-regulation of SOD 
level is an effective and promising strategy to combat UV-induced skin damage. Takahashi et al. 
found that the stable transfection of copper-zinc-SOD expression vectors into human keratinocytes 
could make them more resistant to UVB-induced apoptosis [10]. Decraene et al. reported that a SOD 
mimetic (EUK-134) provided a direct protection against UVB-induced oxidative stress by inhibition 
of the mitogen-activated protein kinase (MAPK) pathways, resulting in a significant increase in 
human keratinocytes survival in vitro [11]. Furthermore, Murakami et al. reported Cu, Zn-SOD 
deficient mice showed more serious atrophic morphology accompanied by the degeneration of 
collagen and elastic fibers in skin, which could be also induced by UV irradiation [12].  
Taking all of above evidence together, it appears that ROS plays a crucial role in mediating the 
deleterious effects induced by UV irradiation. The possibility to introduce exogenous SOD, the 
key intracellular antioxidant enzymes, into keratinocytes would contribute to protection against 
UV-induced skin damage. In an attempt to augment this naturally photoprotective strategy, topical 
application of SOD might be a promising one. To accomplish this goal, it is necessary to develop 
formulations that allow stability of this inherently unstable SOD protein. It is also necessary to 
develop formulations that allow SOD to penetrate through the stratum corneum (SC) in adequate 
concentrations, with few side effects. 
  
 
Transdermal drug therapy is an attractive route of administration because it provides higher patient 
acceptance and compliance and also avoids the first-pass hepatic metabolism. However, a relative 
lack of effective methods to deliver active agents efficiently through the relatively impermeable SC 
has been a major hindrance. Over recent decades, several physical methods, such as electroporation 
and iontophoresis, have been designed to tackle this poor transdermal efficiency, but the results were 
disappointing.  A recent promising technique to deliver bioactive drugs across the epidermal barrier 





[13]. Since the first discovery of HIV-TAT peptide, the cell penetrating peptides have been shown to 
facilitate delivery of a wide variety of biomolecules across cell membrane [14,15]. The potential of 
this technology resides in the high efficiency and relatively low toxicity of CPPs conjugated to 
bioactive cargoes. A remaining challenge is to elucidate their exact uptake mechanisms and 
particularly their transdermal delivery [16]. 
 
Accumulating studies are showing that CPPs can successfully enhance the transdermal absorption of 
therapeutic molecules for the treatment of various skin diseases. Uchida et al. reported that the 
combination of TAT and the tight junction opening AT1002 peptide, effectively accelerated 
transdermal siRNA delivery in mice and strongly suppressed symptoms of atopic dermatitis. [17]. 
Furthermore, Kashio et al. reported that an artificial antiapoptotic protein, FNK, mediated with TAT 
peptide could enter the cochlea and effectively attenuate aminoglycoside-induced apoptosis of 
cochlear sensory hair cells in a guinea pig model [18]. More recently, Ookubo et al. used 
poly-arginine (R11) to enhance transdermal delivery of several tyrosinase inhibitors on a guinea pig 
model and found the fusion protein efficiently penetrated through the SC and significantly inhibited 
UV-induced melanin synthesis [19]. 
 
Although convincing evidence shows that the successful transdermal delivery of various 
biomolecules can be mediated by CPPs in animal or ex vivo models, no transdermal study related 
with SOD has been reported so far. Furthermore, no clinical study based on transdermal application 
of SOD against UV-induced skin damages has yet been investigated. The aim of this study is to 
evaluate whether pretreatment with stratum corneum permeable TAT-SOD protein could 
subsequently attenuate UVB-induced skin damage in man. 
 
2. MATERIALS AND METHODS 
Chemicals 
All reagents used were from Sigma Aldrich unless mentioned. Freeze-dried TAT-SOD recombinant 
protein (310,000 units/mg protein, purity > 98%) was kindly provided by Institute of Biotechnology, 
  
Fuzhou University, China. The TAT-SOD protein is a 164-residue monomeric form of human 




). Molecular weight of this protein 
is 17 kDa. Purified GFP and TAT-GFP recombinant protein were also provided by Institute of 
Biotechnology, Fuzhou University, China. Molecular weights of these two proteins are 26.9 and 28.5 
kDa, respectively. 
 
Ex-vivo skin permeation of TAT-GFP by confocal microscopy  
To evaluate the skin penetration of wild-type GFP and recombinant TAT-GFP, redundant human skin 
from patients who had undergone abdominal plastic surgery was used. Great care was taken to 
maintain the integrity of the skin. The subcutaneous fatty tissue was removed using a scalpel. Skin 
explants of 20 mm in diameter were punched out, sterilized in 70% alcohol for 10s, rinsed in DMEM 
culture medium with antibiotics (Gibco, Paisley, England) 3 times and transferred onto a 6-well 
culture plate. Finally, skin explants were submerged into DMEM culture medium in presence of GFP 
or TAT-GFP at a final protein concentration of 20 μM, and cultured in the 5% CO
2
 incubator at 37℃ 
for up to 2 hours. 
At different endpoints of the penetration experiment (0.5, 1 and 2 hours), 2mm punch biopsies were 
obtained from the center of skin explants with TAT-GFP or GFP pretreatment. The biopsies were 
snap frozen using liquid nitrogen, embedded in O.C.T. embedding medium (Tissue-Tek, Pelco 
International, USA), and sectioned (8 μm, perpendicular to the skin) using a cryostat microtome 
(Leica, Wetzlar, Germany). The sections were visualized with a confocal microscope (Leica, TCS 
SP5, German) at a 20X objective, PMT 800 V, and eGFP filter set (ex 488nm / em 592nm). 
 
Skin permeability of TAT-SOD by tape stripping 
Five healthy volunteers were recruited in this part of study. 2 mg/cm
2
 of two creams were applied on 
two symmetric areas of their both inner upper arms, one containing TAT-SOD protein at 300 
units/cm
2
 (150 units SOD/mg cream), the other a vehicle. After 1 hour pretreatment, the test areas 
were carefully cleaned with ethanol and warm water several times. D-Squame® (CuDerm Corp., 
Dallas, TX, USA) strips, diameter 22 mm, surface area 3.8 cm
2
, were used to sample the SC. Strips 
were placed on the skin, which was outlined with a permanent pen to ensure sampling from the same 
site. Equal pressure was applied to each strip by pressing with a spring-loaded stamp for thirty 
seconds. The comparatively high pressure was a prerequisite for obtaining reproducible amounts of 
SC. Then the strips were removed with tweezers in a single rapid movement and stored on a 
cellophane sheet at -80°C for further analysis. The specific SOD activity was evaluated on a series of 
20 tape stripping samples collected from each subject (n=5).  
 
Detection of SOD activity on tape strips 
The SOD assay was adapted from a well plate method. A D-squame® tape strip was perforated with 
  
a punch and three small pieces (=5 mm) were lined at the bottom of a well of an opaque 96-well 
plate (Corning, Costar, Acton, MA). SOD from bovine erythrocytes was used as an external standard, 
in which case a blank strip was put in the well. SOD activity was assayed using Sigma SOD assay kit 
(19160, Sigma, USA) following the manufacturer's instructions. The reaction started immediately 
when 220 μl of reaction mixture was added to each well. This assay is based on the xanthine/ 
xanthine oxidase catalytic system. After SOD measurement, the tape strips were removed and stored 
in an Eppendorf tube for protein analysis. Specific SOD activity was obtained after normalizing to 
the total protein content on the stripping. 
Protein analysis on tape strips 
The total amount of protein on the D-squame® tape strip was quantified after acid hydrolysis at 
elevated temperature. Each removed tape strip was incubated in an Eppendorf tube containing 1.5 ml 
HCl (6 mol/L) at 120°C for 20 hours for complete hydrolysis. After centrifugation, the supernatant 
was diluted (1: 20) in 1 mol/L borate buffer pH 9. The total protein content was the determined using 
a colorimetric Bradford protein assay (Bradford reagent, Bio-Rad Labs., Hercules, CA) according to 
the microplate working protocol. In the experimental setup, the protein assay was conducted by 
adding 250 μl of cold Bradford Reagent to 25 μl of sample. After 5 minutes incubation at room 
temperature, the optical density was measured with a microplate reader at a wavelength of 595 nm 
(Multiskan EX; Thermo Electron Corporation Vantaa, Finland). The protein content of each removed 
adhesive tape was analyzed in triplicate (n = 3), and the mean value was used for further evaluation. 
Three blank adhesive tapes (n = 3) were respectively extracted in exactly the same fashion as the 
protein-covered tapes, and analyzed with every round of analysis. The mean value of these blank 
tapes served as the respective control to account for background noise. The total protein amount was 
always determined on the same strip as the SOD activity analysis occurred. 
 
UVB source 
A custom made UVB radiation source by Professor Brian Diffey (Regional Medical Physics 
Department, Newcastle, UK) was used for the following UV irradiation experiments. This unit 
consisted of a broadband UVB lamp housed within an enclosed unit, with 10 apertures of 9 mm 
diameter anterior to the UVB lamp to enable 10 incremental doses (38 to 300 mJ/cm
2
) to be 
delivered simultaneously. All 10 apertures were within an area of 7 cm × 3 cm. The maximum dose 
aperture did not contain any metal foil filter, while the other 9-dose apertures were backed by 
perforated metal foil with grids containing holes of differing sizes to allow for the nine increasing 
doses. The UVB lamp casing was made of UV opaque plastic. The unit also consisted of a digital 
photodiode that switched the lamp off automatically when appropriate doses at the apertures were 
delivered. A Philips UVB broadband PL-S 9w/12 (Philips, Eindhoven, Netherlands) lamp with a 
main emission between 275 and 365 nm and maximum at 313 nm was used as UVB source. All 




Ten healthy volunteers with either Fitzpatrick skin type II or III were recruited in this part of study. 
None of the subjects had been exposed to recreational UV radiation or sun beds at least 3 months 
prior to participation, and were using neither topical nor systemic medication at the time of the study. 
The age range was 23~30 y (median, 24 y), and there were three males and seven females. The 
procedures were explained in detail to all subjects. They had provided signed informed consent prior 
to participation. The clinical study was undertaken in accordance with the Declaration of Helsinki 
(http://www.wma. net/e/policy/b3.htm) and was given a favorable ethical opinion by the Lothian 
Regional Ethics Committee (reference number: 10/S1103/38) and the NHS Lothian R&D office 
(reference number: 2010/R/DER/03). The study was performed at the Department of Dermatology, 
University of Edinburgh. 
Before any treatment, two templates with a 7 cm × 3 cm area were marked on two symmetric areas 
of both inner upper arms. Each template contained ten irradiated sub-sites and one non-irradiated 
sub-site. 2 mg/cm
2
 of two creams were applied on the skin, one Dermabase® cream (Paddock 
Laboratories Inc., USA) as a vehicle, the other containing TAT-SOD protein at 300 units/cm
2
 (150 
units SOD/mg cream). To avoid any disruption and maximize the transdermal absorption, two 
pretreated areas were covered by Tegaderm® films (3M Health Care, USA). After one hour 
pretreatment, subjects were instructed to carefully clean the treated areas with ethanol and warm 
water for several times. Then subjects received 10 incremental doses of UVB on two symmetric 
areas of both inner upper arms. Irradiances were from 38 to 300 mJ/cm
2
 of UVB. 24 hours later, 
subjects underwent erythema, blood flow and sunburn cells measurement on pretreated areas.  
 
Determination of minimal erythema dose (MED) 
For all studies requiring assessment of the MED prior to commencement, subjects attended on day 
one when they received ten incremental doses of UVB on both inner upper arms. Subjects returned 
24 hours later to have their MED read. A subject’s MED was defined as the minimal dose producing 
uniform erythema with clearly defined template margins. A Minolta spectrophotometer CM-2600d 
(Minolta Co., Ltd, Osaka, Japan) was used to measure skin color according to a 3-dimensional color 
system (L, a, and b values). The L value referred to lightness of skin; the b value (blue-yellow axis) 
was an indicator of pigmentation; the a value (red-green axis) was a measure of erythema formation 
and the Δa value (a value 24 hours after irradiation minus a value before irradiation) was used to 
measure skin responses to UV irradiation [20]. Each spot was measured in triplicate.  
Blood flow measurement 
  
Cutaneous blood flow, measured as red blood cell flux, was used as another index of erythema. 24 
hours after UVB challenge, the cutaneous blood flow at each irradiated site and adjacent 
non-irradiated skin was measured by a laser Doppler perfusion monitor (MoorLAB, Moor 
Instruments Ltd., Axminster, UK). The perfusion monitor with two satellite units connected to the 
server allowed flux readings from three laser probes to be recorded simultaneously. The perfusion 
monitor was linked to a computer and recordings displayed continuously by MoorSoft v1.31 for 
Windows. During the measurement, the three laser probes were secured to the overlying test sites of 
the skin using a ring of double sided adhesive tape and data were collected for at least 10 minutes, 
from which an average flux was calculated. 
Full thickness punch biopsy 
After MED quantification by colorimetry, four 4 mm punch biopsies were taken from each subject 
under sterile conditions and local anesthesia (Lidocaine 1% + Adrenaline). One was taken from 
non-irradiated, vehicle pretreated skin and served as a negative control. A second biopsy was taken 
from vehicle pretreated skin that had been irradiated with 2 MED of UVB and served as a positive 
control. A third biopsy was taken from non-irradiated, TAT-SOD pretreated skin. A fourth biopsy was 
taken from TAT-SOD pretreated skin that had been irradiated with 2 MED of UVB. In all 
experiments where skin biopsies were taken a 4mm diameter sterile disposable punch biopsy was 
used (Stiefel® Laboratories, Bucks, UK). Biopsy wounds were closed using 4/0 ethilon sutures 
(Ethicon, Johnson and Johnson medical Ltd., W Lothian, UK). All full thickness skin punch biopsies 
were fixed in 4% buffered formaldehyde for 24 hours and embedded in paraffin prior to processing 
for immunohistochemistry. 
 
Measurement of apoptotic sunburn cells 
4 m paraffin-embedded sections of each skin biopsy were deparaffinized through graded alcohol 
and routinely stained with hematoxylin and eosin (H&E) to allow quantification of sunburn cells 
(SBCs). SBCs were identified in the epidermis by their shrunken eosinophilic cytoplasm and 
condensed nuclei. Sections were examined microscopically by two independent counters in a blinded 
fashion for specific histopathological alterations, and images were captured using a 
Hamamatsu CCD camera (C4742095, Hamamatsu, Japan) mounted on a Leica DMR microscope 
with the Leica application suit (ver. 2.8.1, Leica Microsystems, Solms, Germany). Positive cells were 
counted in randomly chosen high power fields (20-fold magnification) from the entire 20-mm length 
of epidermis for each skin section. The results were expressed as the mean number of SBCs per 
section. Positive cells in hair follicles and in the dermis were not included in the quantitative analysis, 




The significance of difference between TAT-SOD and vehicle pretreated groups was analyzed using 
paired, two-tailed, Student’s t-test. Differences between data sets were defined as being significant (*, 
0.05>p>0.01), highly significant (**, 0.01>p>0.001), or very highly significant (***, p<0.001). Data 
were analyzed using Excel 2000 software. All data were presented as mean ± SD. 
 
3. RESULTS AND DISCUSSION 
 
UV absorption spectrum of TAT-SOD protein  
 
Figure 1: (A). UV absorption spectrum of TAT-SOD protein used in this study. (B). Philips 
Broadband UVB PL-S 9w/12 lamp spectrum. (Adapted from Philips phototherapy lamps brochure). 
As can be observed from the absorbance spectrum of protein, some absorption of UV radiation 
occurs at shorter (<300nm) wavelengths of UVB.  Consideration was therefore given to whether 
adding a protein to the cream would produce a biologically protective effect against UVB by simple 
absorption.  
To confirm that the protection of TAT-SOD against UVB irradiation was mainly due to the 
superoxide radical scavenging properties of SOD rather than the physical sunscreen effect of protein 
itself the UV absorption spectra of TAT-SOD protein at different concentrations was first considered. 
In the clinical study 2 mg of TAT-SOD cream (150 units SOD/mg cream) was applied per square 
centimeter of the test area. The concentration of TAT-SOD protein in the cream was 0.5x10
-3
 mg/mL 
which was 200 times lower than the lowest concentration in which the absorption spectrum was 
measured (0.1 mg/mL). Absorption of UVB at this low level would be undetectable. The broadband 
UVB source used for the clinical study emits radiation from 275 to 365 nm with a peak at 313 nm, 
and thus mostly at longer wavelengths than those absorbed by TAT-SOD protein. It is therefore 
unlikely that any biological effects of TAT-SOD could be caused by a physical sunscreen effect.  
 
Visualization of skin penetration of TAT-GFP by confocal microscopy 
To investigate whether TAT peptide could serve as a carrier for transdermal delivery of proteins, 
  
green fluorescent protein (GFP) fused with TAT peptide was used and the skin permeability of GFP 
and TAT-GFP were tested and compared ex vivo. Results examined by confocal microscopy are 
shown in figure 2. As expected, the treatment of skin with wild-type GFP (20 μM) resulted in 
fluorescence that was predominantly localized to the surface of SC and no fluorescence was 
observed in the deeper epidermis and dermis at all time points investigated (figure 2, upper panel). 
This indicates that wild-type GFP has very poor ability to penetrate the SC layer. Conversely, in 
TAT-GFP treated skin (20 μM), strong fluorescence was clearly found in the SC layer and weak 
signals were also observed in the epidermis and dermis at the shortest time of treatment (0.5 hour). 
When the incubation time increased, the fluorescence in epidermis and dermis region was stronger 
and deeper (figure 2, lower panel). Strongest fluorescence was found at the incubation period of 2 h. 
These ex-vivo results demonstrate that TAT-GFP was able to penetrate through the SC layer and 
reach the lower layers of skin. Therefore, we conclude that the skin permeability of TAT-GFP is 
superior to wild-type GFP and this activity is in a time-dependent manner, which strongly indicate 
that the topical application system mediated by TAT peptide reported here has high therapeutic 
potential for the treatment of various skin diseases. 
 
Figure 2. Confocal microscopy of human skin sections with GFP or TAT-GFP treatment under 
different incubation periods (0.5, 1 and 2 hours). Sections were visualized using eGFP filter through 
a 20X objective. Scale bars are 50 μm. The experiment was performed in 6 replicates. Upper panel, 
with GFP treatment; lower panel, with TAT-GFP treatment. 
 
Penetration of TAT-SOD through stratum corneum by tape stripping 
  
 
Figure 3: SOD activities on a series of 20 tape strippings from human stratum corneum with 
TAT-SOD or vehicle pretreatment (n=5). The results are shown as mean ± SD. 
 
Although we have shown that TAT-GFP can efficiently penetrate through the SC layer, no direct 
evidence on TAT-SOD was gained. As the molecular weight of GFP (26.9 kDa) is larger than that of 
SOD (17 kDa), it was expected that TAT-SOD could have better penetration in skin. To investigate 
the skin permeability of TAT-SOD, tape stripping combined with the SOD activity assay was next 
used. Various in vivo methods for measuring transdermal absorption of drugs are available, for 
example blood withdrawal through a venous cannula, microdialysis, and skin blistering [21]. 
Recently, tape stripping has been widely used as a fast and comparatively non-invasive technique to 
measure dermal drug absorption into skin [22,23]. Combined with validated analytical assays for the 
measurement of bioactive substances, tape stripping has been verified as a superior and reproducible 
method to approximate transdermal permeability coefficients and partition coefficients in various 
clinical studies [24,25].  
 
Five volunteers were recruited in this in vivo study. As shown in Figure 3, the specific SOD activity 
was evaluated on a series of 20 tape strip samples collected from each subject using two symmetric 
areas on both of the inner upper arms. In the vehicle pretreated arm, a linear increase of SOD activity 
was found in SC from the surface down to deeper layers. A peak value was detected at layer 14 and a 
plateau was found from layer 14 onward. Such a gradient of SOD activity can be explained by the 
higher levels of environmental oxidative stress, such as UV radiation and air pollution, that the outer 
layers of skin are exposed to, with consequent depletion of antioxidant enzyme availability [26].  
Due to the high efficiency of translocation mediated by TAT peptide, a significant increase of SOD 
activity on the TAT-SOD pretreated arm was found from first layer onward when compared to the 
vehicle pretreated arm. The mean percentage of increase accounted for 250.2% at the first 4 layers 
and 33.9 % from layer 5 onward. These intriguing data also show that the transdermal delivery of 
SOD mediated by TAT peptide could efficiently penetrate through the SC, confirming that the 
topical application system mediated by TAT peptide was effective. Although, the exact mechanism 
  
for transdermal delivery of CPP-linked proteins has not been elucidated, a model of pore formation 
has been proposed to be a more feasible model for the in vivo translocation of large biomolecules, 
like proteins and liposomes [27]. 
 
Suppression of UVB-induced erythema formation by TAT-SOD  
 
Figure 4: (A). Minimal erythema dose (MED) values at 24 hours after UVB irradiation with vehicle 
or TAT-SOD pretreatment were measured by colorimetry. A line links value of vehicle and 
TAT-SOD pretreated skin (300 units/cm
2
 of skin area) in a single subject (n=10). The significance of 
differences (P-value) between two pretreated groups was determined by using paired, two-tailed, 
Student’s t-test. (B). Erythema response at 24 hours after UVB irradiation with vehicle or TAT-SOD 
pretreatment (300 units/cm
2
 of skin area). Tested areas on both of inner upper arms were irradiated 
with 10 incremental doses of UVB. The results are shown as mean ± SD (n=10). 
 
To evaluate the potential protective effect of TAT-SOD on UVB-induced skin damage in human skin, 
three biomarkers were used: erythema, blood flow, and sunburn cell formation. Erythema or sunburn 
redness is an acute and conspicuous cutaneous inflammatory response that follows excessive 
exposure to UV radiation, caused by dilation of the blood vessels in dermis [2, 28]. UVB-induced 
erythema occurs approximately 4 hours after exposure, peaks around 24 hours, and fades over a day 
or so, in fair-skinned and older people [29,30]. Since erythema is readily visible by non-invasive 
methods and can be monitored over time, it has been widely used in photo-biological studies. 
Nevertheless, there have been no published studies looking at the effect of topical application of 
SOD upon UV-induced erythema formation in man. 
 
Ten healthy volunteers (mean age 24 years; range 23–30) participated in this part of the study. Before 
any treatment, two templates with a 7 cm × 3 cm area were marked on two symmetric areas of both 
inner upper arms. Each template contained ten irradiated sub-sites and one non-irradiated sub-site. 
TAT-SOD cream was applied to the template area on one inner upper arm (300 units/cm
2
) and 
vehicle cream on the other. Two pretreated areas were covered by Tegaderm® films (3M Health 
Care, USA) to avoid any disruption. One hour later, the TAT-SOD and vehicle pretreated areas were 
  
carefully cleaned and then irradiated with 10 incremental doses of UVB (from 38 to 300 mJ/cm
2
). 24 
hours after UVB irradiation, MEDs at test areas from ten subjects were measured by colorimetry. 
Results from ten subjects are shown in Figure 4A. Topical application of TAT-SOD caused a 
significant increase in MED in 9 of 10 subjects. The rise of MED was highest in two of phototype II 
subjects, increasing from 95 to 150 mJ/cm
2
 (A 58% increase over vehicle), while in other phototype 
II subjects MED rose from 95 to 119 mJ/cm
2
, which means an increment of 25.3%. MED increment 
in three of phototype III subjects was 26.0% (from 150 to 189 mJ/cm
2 
and 119 to 150 mJ/cm
2
 
respectively) with respect to vehicle. One phototype III subject did show an increase in MED 
following TAT-SOD pretreatment. The significance of differences (P-value) between two pretreated 
groups was determined by using paired, two-tailed, Student’s t-test. Thus, the topical application of 
TAT-SOD cream 1 hour prior to UVB radiation promoted a mean MED increase of 36.6 ± 18.4% (P 
= 0.013<0.05) in 10 subjects, indicating a suppressive effect of TAT-SOD upon UVB induced 
erythema formation. 
 
The mean erythema readings at 10 incremental UVB doses from all 10 subjects are presented in 
Figure 4B. No significant erythema response was detected from 38 to 95 mJ/cm
2
. However, 
TAT-SOD provided protection against erythema formation at all irradiance levels above MED when 
compared with vehicle. The percentage of decrease accounted for 10, 20, 40, and 33% respectively at 
150, 189, 238 and 300 mJ/cm
2
. In addition, none of subjects irradiated with these doses of UVB (up 
to 3 MED) developed clinical signs of skin damage, which excluded the possibility that the topical 
delivery of SOD mediated by HIV-TAT peptide have any adverse effects in skin. 
 
Inhibition of UVB-induced blood flow increment by TAT-SOD  
 
Figure 5: (A). Median blood flow values in vehicle or TAT-SOD pretreated skin (300 units/cm
2
 of 
skin area) were measured at 24 hours after challenge with 2 and 3 MED doses (189 and 300 mJ/cm
2
) 
(n=10). Blood flow values in non-irradiated areas on both of the forearms are shown for comparison 
(0 mJ/cm
2
). The results are shown as mean ± SD. The significance (P-value) between vehicle and 
TAT-SOD groups was determined by using paired, two-tailed, Student’s t-test. (B). A representative 
change in blood flow at 24 hours after 300 mJ/cm
2




 of skin area). The UVB doses of 300 mJ/cm
2
 was selected as equivalent 
to 3-MED for subject 5. 
 
Next, we used cutaneous blood flow as another index of erythema. It was measured as red blood cell 
flux using a laser Doppler perfusion monitor. In previous studies, both Andersen and Youn suggested 
that the blood flow response after UVB irradiation are divided into two phases depending on doses of 
UVB irradiation [31,32]. The cut-off point between two phases is around MED. At doses lower than 
MED, the maximal blood flow response was seen after 8 hours, and at doses higher than MED, the 
maximal response was seen after 24 hours. Furthermore, at higher UVB doses, the resulting increase 
in blood flow was proportional to UVB dose. In order to yield more clear clues on the potential 
protective effect of TAT-SOD towards UVB-induced blood flow response, 2 and 3 MED of UVB 
were used in the following assessments. 
 
Twenty-four hours after UVB challenge, the blood flow of each irradiated and adjacent 
non-irradiated areas were measured. Median blood flow values after challenge with 2 and 3 MED 
(189 and 300 mJ/cm
2
) are shown in Figure 5A. Vehicle pretreated areas showed highly consistent 
and significant increases in blood flow. The median blood flow values following 2 and 3 MED 
increased to 143.6 ± 72.2 units and 322.6 ± 92.7 units respectively, compared to the base line value 
105.2 ± 38.6 units. In the meantime, much lower blood flow increments were found in TAT-SOD 
pretreated areas. The median blood flow rise following 2 and 3 MED were 107.8 ± 51.0 units and 
239.5 ± 88.0 units respectively, which accounted for a 26 % and 25 % decrease with respect to 
vehicle group. A representative change in blood flow at 24 hours after 300 mJ/cm
2
 UVB irradiation 
with vehicle or TAT-SOD pretreatment (300 units/cm
2
 of skin area) is shown in Figure 5B. The 
UVB doses of 300 mJ/cm
2
 was selected as equivalent to 3-MED for subject 5. The mean blood flow 
values in the TAT-SOD pretreated area significantly decreased from 277.0 ± 37.1 units to 189.3 ± 
32.0 units compared with the vehicle pretreated area. These data suggest that TAT-SOD has a 
significantly suppression upon UVB induced blood flow increment. In addition, the median blood 
flow values measured at non-irradiated sites with vehicle and TAT-SOD pretreatment were not 
significantly different, indicating that there was no adverse effect on topical application of SOD 
mediated by HIV-TAT peptide. 
 
Reduction on UVB-induced apoptotic sunburn cell formation by TAT-SOD 
Finally, the effect of TAT-SOD pretreatment on SBC formation following UVB irradiation was 
investigated. SBCs, which are well known as apoptotic keratinocytes, are mainly present in the 
epidermis and reach a maximum density at about 24 hours after UVB irradiation [33,34]. When 
stained with H&E, they are easily identified morphologically with a condensed nucleus and a 
shrunken glassy, eosinophilic cytoplasm [35]. As previous studies reported that SBCs are absent or 
rare after UVA irradiation [36,37], SBC formation in the epidermis has been widely used as a 
biomarker of UVB induced skin damages. 
  
 
Figure 6: (A) Representative images of specimens stained for SBCs at the UVB-irradiated site and 
non-irradiated site (taken from subject 6). The SBC in the epidermis is indicated above the figures 
with an arrow. (B) The graph shows mean numbers of SBCs per section in all the test areas. Each 
specimen was subjected to H&E staining and photographed at a magnification of x20; scale bar = 50 
µm. The number of SBCs was significantly decreased by TAT-SOD applied 1 hour before UVB 
  
irradiation. No sunburn cells were found at the non-irradiated areas pretreated with vehicle or 
TAT-SOD. Data are presented as means ± SD. P values shown are for comparison to TAT-SOD 
pretreatment (n = 10, paired, two-tailed, Student’s t-test). 
 
Ten healthy volunteers were involved in this part of study. 24 hours after UVB irradiation, four 4mm 
punch biopsies were taken from 2-MED irradiated areas with TAT-SOD and vehicle pretreatment, as 
well as from the adjacent, non-irradiated areas with TAT-SOD and vehicle pretreatment. The amount 
of SBCs was quantified from paraffin-embedded sections of each skin biopsy staining with H&E and 
expressed as a mean number of SBCs per section. SBCs were identified in the epidermis by their 
shrunken eosinophilic cytoplasm and condensed nuclei.  
 
In Figure 6A shows the epidermal localization of SBCs at 24 hours after 2-MED of UVB irradiation. 
Non-irradiated areas contained no SBCs, but SBCs were clearly present at 24 hours post-irradiation 
on irradiated area. In normalized data from all ten subjects, the mean numbers of SBCs in 2-MED of 
UVB irradiated areas with vehicle and TAT-SOD pretreatment were 21 ± 5 and 11 ± 4 per section 
respectively. Hence, the pretreatment with TAT-SOD (300 units/cm
2
) 1 hour prior to 2-MED of UVB 
irradiation significantly reduced the apoptotic SBCs formation by 47.6 ± 8.6 % (P<0.0001). In 
addition, the numbers of SBCs in non-irradiated areas with vehicle or TAT-SOD pretreatment were 
both zero, indicating that no adverse effect was found in skin upon TAT-SOD pretreatment. These 
data suggest that the TAT-SOD pretreatment, 1 hour prior to UVB irradiation, significantly decreases 
SBC formation. 
 
It has been realized that the importance of SBC goes far beyond that of an alternative biomarker for 
acute UVB injury. Numerous studies have suggested that the number of SBC which highly correlates 
with keratinocyte apoptosis is mainly mediated by the severity of DNA damage [38]. Two 
mechanisms protect against the consequences of UV-induced DNA damage. These are growth arrest 
followed by DNA repair and cell death by apoptosis. After a low dose of UV, most photo-lesions are 
removed by two major pathways of DNA repair: nucleotide excision repair and base excision repair, 
resulting in cell survival [39]. After a high UV dose, DNA damage will overwhelm the repair 
capacity of cell and cells subsequently go into programmed cell death (apoptosis). Through apoptosis, 
severely damaged keratinocytes will die and be eliminated as SBCs, thereby reducing the risk of 
further mutations which can lead to skin malignant transformation [33,34]. Accordingly, an increase 
of DNA repair following UV irradiation should result in a reduced ratio of SBCs. On the other hand, 
the reduced appearance of SBCs would indicate greater photocarcinogenic risk [40]. Indeed, there is 
confusion in interpreting the significance of SBCs for acute photodamage and long-term 
photocarcinogenesis. 
 
Current data demonstrate that TAT-SOD plays an antiapoptotic role that we speculate indicates a 
reduced rather than increased susceptibility to photocarcinogenesis. The photoprotection afforded by 
  
sunscreens produces a reduction in SBC number, consequently leading to potential protection against 
photocarcinogenesis [41,42]. Furthermore, several studies in mice showed that the inhibition of 
photocarcinogenesis is strictly associated with reduced SBC number. [43-45]. Because of only one 
dose of UVB (2-MED) was used to evaluate the potential effect of TAT-SOD on SBCs formation, 
and no marker for DNA damage was involved in the present study, the detailed mechanisms 
underlying these photoprotective effects of TAT-SOD are not well understood. It is not known 
whether TAT-SOD will increase SBC number following higher UVB doses than 2-MED, with 
improved regulation of DNA repair in skin. It may be that the protective effects of TAT-SOD against 
UVB-induced skin damages are highly UVB dose-dependent. Further studies using a wider range of 
UVB doses would clarify the effect TAT-SOD upon DNA damage in skin.  
 
4. CONCLUSIONS 
This is the first comparative clinical study on topical application of a permeable TAT-SOD protein 
against UVB-induced damage in human skin. We demonstrated that the transdermal delivery of SOD 
through SC was successfully achieved by mediating with HIV-TAT peptide. By replenishing the 
antioxidant defense of keratinocytes, TAT-SOD reduced markers of acute UVB-induced skin 
damage, erythema response, blood flow increment, and SBC formation. These biological effects of 
TAT-SOD are probably mediated via its radical scavenging properties, differentiating it from other 
physical sunscreen agents. Further studies are planned with the intention of evaluating whether the 
protective effects of TAT-SOD against UVB-induced skin damages are mediated via the inhibition 
of p53 gene or thymine dimer formation pathway. The mechanism by which TAT-SOD prevents 
UVB-induced skin damages remains to be fully elucidated as well as whether sustained application 
of TAT-SOD might prevent chronic UV damage over time, such as photoaging and 
photocarcinogenesis. In summary, the above results re-emphasize the importance of oxidative stress 
as an initiator of UVB-induced skin damage and also indicate that the transdermal protein/peptide 
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 Topical application of superoxide dismutase is mediated with HIV-TAT peptide. 
 TAT-SOD protein efficiently penetrated through the stratum corneum. 
 TAT-SOD protein significantly attenuated UVB-induced skin damage in man. 
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